Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the board to serve as chief innovation officer.
Timney has over 25 years of biopharmaceutical industry experience in multi-national companies.
At Merck and Co (NYSE: MRK), Timney led organisations of increasing importance and size, including president US, president Japan and president of Global Primary Care.
In these roles, Timney launched multiple products, many in the cardiovascular therapeutic area, led large organisations of up to 8,000 employees, and was involved in a number of important strategic transactions.
After leaving Merck, Timney served as the CEO of Purdue Pharmaceuticals and formed a company advising healthcare companies.
Before joining Merck, Timney spent eight years working at numerous multinational pharmaceutical companies, including Zeneca Group, ICI Pharmaceuticals and Roussel Labs.
The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare.
The company's goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. The company is headquartered in Parsippany, New Jersey.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer